Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Status:
Withdrawn
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
ENGOT-OV42 / NSGO-AVATAR: This three-arm randomized trial is to demonstrate efficacy of
niraparib-bevacizumab-dostarlimab triplet combination against standard of care treatment and
to demonstrate efficacy of niraparib-bevacizumab-dostarlimab triplet combination against
niraparib-bevacizumab doublet combination for patients with platinum-sensitive epithelial
ovarian, fallopian tube, or peritoneal cancer
Phase:
Phase 3
Details
Lead Sponsor:
Nordic Society for Gynaecologic Oncology Nordic Society of Gynaecological Oncology - Clinical Trials Unit